

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
Telephone : (609) 252-6385
Fax: (609) 252-4526

FACSIMILE TRANSMISSION

To: Examiner R. L. Anderson
U.S.P.T.O.

Date: September 10, 2003

Fax No.: (703) 746-7444

cc:

From: Terence J. Bogie

Pages: 13 (including cover)

THIS FACSIMILE CONTAINS PRIVILEGED OR CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE USE OF THE ADDRESSEE(S). EXCEPT FOR DELIVERY TO THE INTENDED RECIPIENT, ANY DISSEMINATION OR COPYING OF THIS FACSIMILE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS FACSIMILE IN ERROR, PLEASE NOTIFY US AND RETURN THE ORIGINAL TO US AT THE ABOVE ADDRESS.

Re: Response to Advisory Action of September 2, 2003
USSN 10/027,982
Our Reference: QA0238 NP

Examiner Anderson:

Thank you for speaking with me on Monday, September 8, 2003, regarding the above-identified case. As per our conversation of September 8, 2003, the claims have been amended to further clarify subject matter that the applicants believe meets the statutory requirements for allowance.

If you have any questions or this facsimile is illegible, please do not hesitate to contact me at the telephone number set forth above.

Thank you for your assistance in this matter.

Sincerely,



Terence Bogie
Attorney for the Applicants

CASE QA0238 NP

CERTIFICATE OF TRANSMISSION (37 CFR 1.8a)	
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. (703) 746-7444 on September 10, 2003.	
Terence J. Bogle Type or print name	<u>Terence J. Bogle</u> Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1626

BARRISH ET AL.

Examiner: Rebecca L. Anderson

APPLICATION NO: 10/027,982

FILED: DECEMBER 20, 2001

FOR: THIAZOLYL INHIBITORS OF TEC FAMILY TYROSINE KINASES

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an amendment in the above-identified application.

Fee calculation:

Multiple Dependent Claims (\$ 280)							\$
For	Number Presented	Number Prev. Paid	Number Extra		Rate		
TOTAL CLAIMS	14	- 22	= 0	x	\$ 18	=	\$ 0
INDEPENDENT CLAIMS	1	- 3	= 0	x	\$ 84	=	\$ 0
TOTAL FEE							\$ 0


- ☒ No additional fee is required. The Commissioner is hereby authorized to charge any additional fees under 37 C.F.R. §1.16 and §1.17, which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,


Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000

(609) 252-6386

Date: September 10, 2003


Terence J. Bogie
Attorney for Applicants
Registration No. 44,544

CASE QA0238 NP

CERTIFICATE OF TRANSMISSION (37 CFR 1.8a)	
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. (703) 746-7444 on September 10, 2003.	
Terence J. Bogie Type or print name	 Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1626

BARRISH ET AL.

Examiner: Rebecca L. Anderson

APPLICATION NO: 10/027,982

FILED: DECEMBER 20, 2001

FOR: THIAZOLYL INHIBITORS OF TEC FAMILY TYROSINE
KINASESMail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**RESPONSE TO ADVISORY ACTION**

Sir:

Applicants respectfully request a one-month extension of time. Please charge the one-month extension of time fee of \$110, as well as any additional fees, to Deposit Account Number 19-3880.

Applicants filed a Notice of Appeal in the above-identified application on August 7, 2003. An Advisory Action was issued in the above-identified application on September 2, 2003. Applicants respectfully request that the above-identified patent application be amended, without prejudice, as follows:

Amendments to the Claims are reflected in the amendments in the listing of claims, which begins on page 2 of this paper.

Remarks/Arguments begin on page 9 of this paper.